Lantheus Holdings, Inc. Purchase Obligation, to be Paid, Year One
Lantheus Holdings, Inc. (LNTH) had Purchase Obligation, to be Paid, Year One of $14.78 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Purchase Obligation, to be Paid, Year One $14.78M.
- 2024-12-31: Purchase Obligation, to be Paid, Year One $5.92M.
- 2023-12-31: Purchase Obligation, to be Paid, Year One $2.72M.
- 2022-12-31: Purchase Obligation, to be Paid, Year One $5.72M.
| Period end | Purchase Obligation, to be Paid, Year One |
|---|---|
| 2025-12-31 | $14.78M 10-K · filed 2026-02-26 |
| 2024-12-31 | $5.92M 10-K · filed 2025-02-26 |
| 2023-12-31 | $2.72M 10-K · filed 2024-02-22 |
| 2022-12-31 | $5.72M 10-K · filed 2023-02-23 |
| 2021-12-31 | $3.48M 10-K · filed 2022-02-24 |
| 2020-12-31 | $4.13M 10-K · filed 2021-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-25 |
| 2018-12-31 | $0.00 10-K · filed 2019-02-20 |
| 2017-12-31 | $0.00 10-K · filed 2018-02-26 |
| 2016-12-31 | $0.00 10-K · filed 2017-02-23 |
| 2015-12-31 | $0.00 10-K · filed 2016-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |